2017 Molecular Biology Research 
Drug Target Review
JULY 7, 2025
Persistent challenges with NHP use Despite their biological relevance, using live NHPs in research poses several major challenges: Ethical concerns NHPs, due to their advanced cognition and social behaviour, are at the centre of ongoing ethical debates. Supply chain disruptions Availability is a critical bottleneck in NHP-based research.
Codon
JUNE 5, 2025
Researchers have since discovered variants of the protein with additional useful qualities. Researchers have also discovered a slew of small Cas9s — some less than half the size of the S. By cutting DNA with CRISPR, researchers can therefore scramble the genetic code in a way that disables the targeted gene.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
SEPTEMBER 22, 2023
Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. The derived drug was given to both patients, to which researchers report the patients saw significant improvement. Nat Rev Neurol [Internet].
Broad Institute
APRIL 22, 2024
Jennifer Listgarten By Rose Circeo April 22, 2024 Jennifer Listgarten Jennifer Listgarten is a Professor in the Department of Electrical Engineering and Computer Science, the Center for Computational Biology, and the Bioengineering program at the University of California, Berkeley. She completed her Ph.D.
Drug Target Review
APRIL 19, 2024
After ten years of exciting postdoctoral research around Europe in the astroparticle physics sector, hunting for dark matter at yet another offer from a foreign institution, I chose to create space for my life instead. Pure theoretical research is not in my chords, and I felt uncomfortable not being challenged by data. To participate.
Drug Target Review
FEBRUARY 28, 2024
Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers. Mr Ho has worked in the biotechnology industry for almost 20 years.
Drug Target Review
JUNE 19, 2024
Because this programme is still in early research, we are not at a point we can say we definitely know what it is going to work best in setting X or setting Y. Prior to joining Lineage, Mr Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. SVRA) in April 2017.
Expert insights. Personalized for you.
52 
Let's personalize your content